Nevro (NVRO) Stock Price, News & Analysis

Company Overview

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.

Key Stats

• Today's Range: $5.84 to $5.85
• 50-Day Range: $4.57 to $5.85
• 52-Week Range: $3.17 to $14.70
• Volume: 222,949 shs
• Average Volume: 725,746 shs
• Market Capitalization: $224.28 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.43
• Consensus Rating: Reduce

Nevro Stock Analysis - MarketRank™

Nevro scored higher than 18% of companies evaluated by MarketBeat, and ranked 878th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Reduce

Consensus Rating

Nevro has received a consensus rating of Reduce. The company's average rating score is 1.92, and is based on 1 buy rating, 10 hold ratings, and 2 sell ratings.

Amount of Analyst Coverage

Nevro has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Nevro are expected to decrease in the coming year, from ($2.44) to ($2.51) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Nevro is -3.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nevro is -3.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Nevro has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.66% of the float of Nevro has been sold short.

Short Interest Ratio / Days to Cover

Nevro has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nevro has recently decreased by 7.14%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nevro does not currently pay a dividend.

Dividend Growth

Nevro does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.66% of the float of Nevro has been sold short.

Short Interest Ratio / Days to Cover

Nevro has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nevro has recently decreased by 7.14%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.0 / 5
• News Sentiment: -0.27

News Sentiment

Nevro has a news sentiment score of -0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Nevro this week, compared to 4 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Nevro insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.20% of the stock of Nevro is held by insiders.

Percentage Held by Institutions

95.52% of the stock of Nevro is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NVRO Stock Analysis - Frequently Asked Questions

How have NVRO shares performed this year?

Nevro's stock was trading at $3.72 at the beginning of 2025. Since then, NVRO shares have increased by 57.1% and is now trading at $5.8450.
View the best growth stocks for 2025 here.

How were Nevro's earnings last quarter?

Nevro Corp. (NYSE:NVRO) announced its earnings results on Tuesday, March, 4th. The medical equipment provider reported ($0.64) EPS for the quarter, beating analysts' consensus estimates of ($0.79) by $0.15. The medical equipment provider had revenue of $105.55 million for the quarter, compared to the consensus estimate of $102.61 million. Nevro had a negative net margin of 16.54% and a negative trailing twelve-month return on equity of 23.52%.

Who are Nevro's major shareholders?

Top institutional shareholders of Nevro include ArrowMark Colorado Holdings LLC (11.64%), D. E. Shaw & Co. Inc. (4.81%), UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (2.49%) and Geode Capital Management LLC (2.21%). Insiders that own company stock include Kashif Rashid and Shawn Mccormick.
View institutional ownership trends.

How do I buy shares of Nevro?

Shares of NVRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Nevro own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Nevro investors own include American Water Works (AWK), Waste Connections (WCN), Humana (HUM), The RMR Group (RMR), DiamondRock Hospitality (DRH), Voyager Therapeutics (VYGR) and AUO (AUOTY).

Company Calendar

• Last Earnings: 3/04/2025
• Today: 3/28/2025
• Next Earnings (Estimated): 5/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:NVRO
• CIK: 1444380
• Web: www.nevro.com
• Phone: (650) 251-0005
• Fax: N/A
• Employees: 1,215
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $6.43
• High Stock Price Target: $16.00
• Low Stock Price Target: $4.00
• Potential Upside/Downside: +9.9%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.92
• Research Coverage: 13 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.05)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-92,210,000.00
• Net Margins: -16.54%
• Pretax Margin: -17.89%
• Return on Equity: -23.52%
• Return on Assets: -10.83%

Debt

• Debt-to-Equity Ratio: 0.67
• Current Ratio: 5.02
• Quick Ratio: 3.76

Sales & Book Value

• Annual Sales: $408.52 million
• Price / Sales: 0.55
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.10 per share
• Price / Book: 0.72

Miscellaneous

• Outstanding Shares: 38,372,000
• Free Float: 36,273,000
• Market Cap: $224.28 million
• Optionable: Optionable
• Beta: 0.94